Back to Search Start Over

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

Authors :
Georg Mann
Anne Uyttebroeck
Denise Williams
Wilhelm Woessmann
Emanuele S.G. d'Amore
Christine Damm-Welk
Elisa Carraro
Atsuko Nakazawa
Suzanne D. Turner
Auke Beishuizen
Rafael Fernández-Delgado Fernández-Delgado Cerdá
Birgit Burkhardt
Marie-Cécile Le Deley
Andishe Attarbaschi
Monika Csóka
Lara Mussolin
Laurence Brugières
Amos Burke
Wolfram Klapper
Alfred Reiter
Keizo Horibe
Laurence Lamant
Karin Mellgren
Grażyna Wróbel
Attarbaschi, Andishe [0000-0002-9285-6898]
Turner, Suzanne D. [0000-0002-8439-4507]
Apollo - University of Cambridge Repository
Turner, Suzanne D [0000-0002-8439-4507]
Source :
Cancers, Vol 12, Iss 2747, p 2747 (2020), Cancers, Volume 12, Issue 10
Publication Year :
2020
Publisher :
MDPI AG, 2020.

Abstract

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). Analysis of minimal disseminated disease (MDD), available for 162 patients, showed that both SC/LH pattern (hazard ratio = 2.4) and MDD positivity (hazard ratio = 2.15) were significantly associated with risk of failure in multivariate analysis. Considering MDD and SC/LH results, patients were separated into three biological/pathological (bp) risk groups: a high-risk group (bpHR) including MDD-positive patients with SC/LH pattern<br />a low-risk group (bpLR) including MDD-negative patients without SC/LH pattern<br />and an intermediate-risk group (bpIR) including remaining patients. The 10-year PFS was 40%, 75% and 86% for bpHR, bpIR and bpLR, respectively (p &lt<br />0.0001). These results should be considered in the design of future ALCL trials to tailor individual treatments.

Details

ISSN :
20726694
Volume :
12
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....3c2d019eefb2e1442f19e4074f3d27e5